Read by QxMD icon Read

Clinical Neuropharmacology

Beatriz Camarena, Deni Álvarez-Icaza, Sandra Hernández, Alejandro Aguilar, Lucía Münch, Consuelo Martínez, Claudia Becerra-Palars
OBJECTIVE: Pharmacogenetic studies have identified genetic variants associated with fluoxetine response in patients with major depression disorder (MDD). The serotonin transporter gene is the principal site of action of selective serotonin reuptake inhibitors. Previous studies analyzing SLC6A4 gene variants are inconsistent and differ among populations. The aim of the present study was to analyze the association between 5-HTTLPR/rs24531 triallelic polymorphism and fluoxetine response in Mexican patients with MDD...
December 4, 2018: Clinical Neuropharmacology
Nishit B Modi, Aravind Mittur, Robert Rubens, Sarita Khanna, Suneel Gupta
OBJECTIVE: IPX203 is an investigational oral extended-release capsule formulation of carbidopa-levodopa (CD-LD). The aim of this study was to characterize the single-dose pharmacodynamics, pharmacokinetics, and safety of IPX203 in subjects with advanced Parkinson disease compared with immediate-release (IR) CD-LD and extended-release CD-LD (Rytary). METHODS: This was a randomized, open-label, rater-blinded, multicenter, single-dose crossover study. Blinded clinicians assessed subject's motor state and Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III scores for up to 10 hours postdose...
December 4, 2018: Clinical Neuropharmacology
Ashhar Ali, Jennifer Kriegler, Stewart Tepper, Brinder Vij
OBJECTIVE: The aim of the study was to determine whether onabotulinumtoxinA therapy is effective in the treatment of new daily persistent headache (NDPH). BACKGROUND: New daily persistent headache is a difficult to treat headache syndrome resistant to both conventional and unconventional headache therapies. New daily persistent headache was excluded in the registration trials for onabotunlinumtoxinA (onabot) in chronic migraine. Apart from case reports supporting its benefit, little is known about its therapeutic value in NDPH...
November 28, 2018: Clinical Neuropharmacology
Ido Lurie, Ori Ganor, Gad Mayer
Bupropion is antidepressant and a smoking cessation aid medication related to dopaminergic activity. We report for the first time a case of an older adult with a known tic disorder, which was in remission but exacerbated during treatment with bupropion. It has been reported that other dopaminergic compounds such as methylphenidate can exacerbate tic disorder. Clinicians should be aware of this potential adverse effect when prescribing bupropion to adults with tic and other motor disorders.
November 28, 2018: Clinical Neuropharmacology
Ayhan Bilgiç
Hiccup is a sudden-onset repeated involuntary and spasmodic contraction of the diaphragm and intercostal muscle accompanied by laryngeal closure, generating the characteristic inspiratory sound and discomfort. Various factors including drugs may trigger the hiccups. There are some reports regarding the possible links between psychotropic agents that can affect the dopaminergic system and the triggering of hiccup; however, to our knowledge, there are no data regarding sertraline-induced hiccup. We present the case of a boy with obsessive-compulsive disorder and attention-deficit/hyperactivity disorder who displayed hiccup after sertraline therapy...
November 5, 2018: Clinical Neuropharmacology
(no author information available yet)
No abstract text is available yet for this article.
January 2019: Clinical Neuropharmacology
İsmail Akaltun
Trichotillomania (TTM) is a disorder characterized by the individual pulling out his hair in a repetitive manner, resulting in significant hair loss, a feeling of tension before the hair pulling, and pleasure during it. Our understanding of the neurobiological basis of TTM is limited. However, the condition in all likelihood involves multiple pathways and a complex interaction between various genetic, psychological, and social factors. Vitamin D deficiency is thought to be linked to rickets in children and to a range of different diseases in adults, including osteoporosis, osteomalacia, cardiovascular diseases, cancer, dermatological diseases, and psychiatric disorders...
January 2019: Clinical Neuropharmacology
Carolina C Ramírez-Gómez, Carlos Zúñiga-Ramírez, María Laura Contartese, Verónica Montilla, Jorge Gramajo, Federico Micheli
OBJECTIVES: The aim of the study was to report 4 patients with Parkinson disease (PD) and On-period blepharospasm (BS). METHODS: We analyzed patients with PD and motor fluctuations who developed BS in several different centers in Latin America. RESULTS: Four patients had BS while in the ON periods. CONCLUSIONS: Blepharospasm in the On period in patients with PD is extremely uncommon, and our series is the only one to describe such association...
January 2019: Clinical Neuropharmacology
Yifan Liang, Quhong Song, Yang Jiao, Jueying Lin, Huiling Qu, Shanshan Zhao, Junjie Xu, Chuansheng Zhao, Mei Zhao
OBJECTIVES: The objective of this study was to investigate the safety of anticoagulation in ischemic stroke (IS) patients with cerebral microbleeds (CMBs). METHODS: PubMed, Web of Science, Elsevier Clinical Key, Google Scholar, and Cochrane Library from 1996 to July 2018 were searched to identify relevant studies that included IS patients, underwent T2*-weighted gradient recalled echo, or susceptibility-weighted imaging for detection CMBs and used anticoagulants during follow-up...
November 2018: Clinical Neuropharmacology
Cristian Eduardo Navarro, Paula Juliana Rodríguez, Oscar Mauricio Espitia
Posterior reversible encephalopathy syndrome is a disorder of reversible subcortical vasogenic brain edema in the context of different diseases or exposure to cytotoxic drugs such as fludarabine. We present the case of a pediatric patient with β-thalassemia who develops a fludarabine-induced posterior reversible encephalopathy while he received an induction regimen to achieve an allogenic hematopoietic cell transplantation. The clinical presentation consists in altered mental state, headache, status epilepticus, visual disturbance, and hypertension...
November 2018: Clinical Neuropharmacology
Grace H Lee, Jonathan T Stewart
Musical hallucinations (MHs) are relatively uncommon phenomena sometimes encountered in older patients, especially older women. They usually involve popular, overlearned music, either entire songs or repetitive snippets. While MHs are most commonly associated with hearing loss, they may occur in a variety of psychiatric, neurologic, and iatrogenic conditions. We report a 91-year-old man whose MHs were causally related to the antidepressant mirtazapine. Although mirtazapine is generally well tolerated, it may rarely cause MHs or other psychotic symptoms...
November 2018: Clinical Neuropharmacology
Neepa Patel, Peter LeWitt, Ariel B Neikrug, Patrick Kesslak, Bruce Coate, Sonia Ancoli-Israel
INTRODUCTION: Impaired nocturnal sleep and excessive daytime sleepiness are common problems for patients with Parkinson's disease, and patients with Parkinson's disease with sleep dysfunction are 5 times more likely to experience psychotic symptoms. Pimavanserin, a 5-HT2A inverse agonist approved to treat Parkinson's disease psychosis, may improve sleep quality in patients with Parkinson's disease experiencing sleep disturbances. METHODS: Scales for Outcomes in Parkinson's Disease nighttime sleep (SCOPA-NS) and SCOPA-daytime sleepiness (DS) data obtained during 2 double-blind placebo-controlled studies of pimavanserin in persons with Parkinson's disease psychosis were evaluated...
October 9, 2018: Clinical Neuropharmacology
Elena de Celis, María Alonso de Leciñana, Jorge Rodríguez-Pardo, Blanca Fuentes, Exuperio Díez-Tejedor
OBJECTIVE: The aim of the study was to illustrate the increased risk of ischemic stroke in the context of multiple myeloma (MM) under treatment with lenalidomide combined with dexamethasone. METHODS: This is a case report and literature review. RESULTS: A 62-year-old woman diagnosed with relapsed MM under treatment with lenalidomide and dexamethasone presented with acute onset disorientation, disturbed behavior, and aphasia. Cranial computed tomography scan revealed an acute cerebral infarction in the left middle cerebral artery territory, and brain magnetic resonance imaging showed additional silent ischemic lesions in other arterial territories...
September 28, 2018: Clinical Neuropharmacology
Ching-Wen Chu, Chih-Sung Liang, Fang-Jung Wan
No abstract text is available yet for this article.
September 28, 2018: Clinical Neuropharmacology
Leonid Kapulsky, Benjamin D Brody
Urinary retention is a well-documented adverse effect of antipsychotic medications and is thought to be mediated by anticholinergic, adrenergic, and other neurotransmitter effects. Whereas urinary retention has been reported with typical and some atypical antipsychotics, there have been no reports of urinary retention with the novel antipsychotic cariprazine. We report on a case of urinary retention associated with cariprazine. Possible mechanisms for this adverse effect are discussed.
September 28, 2018: Clinical Neuropharmacology
Emilija Cvetkovska, Igor Kuzmanovski, Marija Babunovska, Bojan Boshkovski, Katina Aleksovska, Gordana Kiteva Trencevska
OBJECTIVES: The choice of antiepileptic drug is typically based on seizure type, and there is no evidence for superior effectiveness or potential deterioration of particular antiepileptic drug in specific etiologic subgroups. The aim of the study was to identify etiological factor(s) associated with increased risk of seizure aggravation with levetiracetam (LEV). METHODS: A retrospective analysis of 139 patients treated with LEV was performed. Seizure aggravation was defined as a 100% or greater increase in seizures frequency, which occurred within 1 month of drug introduction...
September 18, 2018: Clinical Neuropharmacology
Hussein Algahtani, Bader Shirah, Hind Abobaker, Nebras Alghanaim, Fatemah Kamel
BACKGROUND: Natalizumab is the first targeted humanized monoclonal antibody to be approved for the treatment of relapsing-remitting multiple sclerosis (RRMS). Natalizumab appears to be more effective than current first-line disease-modifying therapies. In our study, we aimed to evaluate the outcome of Saudi patients with active RRMS treated with natalizumab and compare the results with other outcomes in the Gulf and international trials. METHODS: We conducted a retrospective single-center observational study involving 32 patients with RRMS at King Abdulaziz Medical City in Jeddah, Saudi Arabia...
September 18, 2018: Clinical Neuropharmacology
Kensuke Miyazaki, Masabumi Otaka, Norio Yasui-Furukori
BACKGROUND: Rhabdomyolysis involves the release of intracellular contents secondary to muscle cell injury; it generally presents with muscle pain and weakness. Although several psychotropic agents have been documented as causes of rhabdomyolysis, there are no reports of tandospirone-induced rhabdomyolysis. CASE: We present the case of a 15-year-old Japanese girl who had posttraumatic stress disorder after the Great East Japan Earthquake. She received a dose of 60 mg of tandospirone while taking 10 mg of tandospirone and 400 mg of valproic acid every day...
September 10, 2018: Clinical Neuropharmacology
María Verónica Rey, Luis Molina, Byron Recinos, Bezner Paz, Mauricio Rovelo, Fanny Elizabeth Rodriguez Elias, José Calderón, Arturo Arellano, Santiago Perez-Lloret
OBJECTIVES: The aims of the study were to explore the frequency of movement disorders (MDs) in depressive patients exposed to antipsychotic drugs (APDs) and to compare it with nonexposed depressive patients and APDs-treated schizophrenic patients. METHODS: Four hundred fifty-two depressive patients not exposed to APDs (group A), 156 depressives exposed to APDs (group B), and 75 patients with schizophrenia on APDs (group C) were recruited. Presence of MDs was explored by the Simpson-Angus and UKU scales (Registration: NCT02409823)...
September 2018: Clinical Neuropharmacology
Tsuyoshi Miyaoka, Misako Kanayama, Rei Wake, Sadayuki Hashioka, Maiko Hayashida, Michiharu Nagahama, Shihoh Okazaki, Satoko Yamashita, Shoko Miura, Hiroyuki Miki, Hiroyuki Matsuda, Masahiro Koike, Muneto Izuhara, Tomoko Araki, Keiko Tsuchie, Ilhamuddin Abdul Azis, Ryosuke Arauchi, Rostia Arianna Abdullah, Arata Oh-Nishi, Jun Horiguchi
AIM: Up to 60% of depressed patients do not obtain sufficient relief from a course of antidepressant therapy, and these treatment-resistant major depressive disorder (TRD) patients are at increased risk for relapse, chronicity, persistent psychosocial impairments, and suicide. Probiotics actively participate in treatment of neuropsychiatric disorders. However, the role of gut microbiota in brain disorders and depression remains unclear. We performed a prospective study to evaluate the effects of Clostridium butyricum MIYAIRI 588 (CBM588)...
September 2018: Clinical Neuropharmacology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"